ArticleFrontiers in microbiology2026
Annexin A2 facilitates Japanese encephalitis virus replication by regulating endocytosis and intracellular transport in PK15 cells.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Japanese encephalitis virus (JEV) is a mosquito-borne flavivirus that causes severe encephalitis in humans and reproductive disorders in pigs. However, the host factors that regulate JEV infection and replication remain incompletely understood. Method: In this study, we used porcine kidney cells (PK15) infected with the attenuated JEV strain SA14-14-2 to identify host proteins interacting with the JEV envelope (E) protein by immunoprecipitation coupled with LC-MS/MS. Results: Annexin A2 (ANXA2) was identified as a candidate host factor associated with JEV infection. ANXA2 expression was increased during JEV infection, and co- immunoprecipitation confirmed its association with the JEV E protein. Inhibition of ANXA2 with antibody reduced JEV RNA replication in a dose-dependent manner. To further define its function, ANXA2 knockout (KO) PK15 cells were generated using CRISPR/Cas9. Compared with wild-type cells, ANXA2-KO cells showed significantly reduced viral RNA accumulation, especially during the early stage of JEV infection (2-6hpi), when the viral entry and initiates replication, lower JEV E protein expression, and decreased progeny virus titers. In addition, ANXA2 deficiency altered the expression of clathrin-mediated endocytosis- related genes and proteins, including CLTC, CLTB, AP2M1, and EPS15, and affected Akt phosphorylation during early infection. Fluorescence recovery after photobleaching analysis (FRAP) of DiD-labeled JEV particles indicated impaired intracellular transport in ANXA2-KO cells. Discussion: these findings identify ANXA2 as a host factor that promotes JEV infection and replication, at least in part by regulating clathrin-mediated endocytosis and intracellular transport. ANXA2 may represent a potential target for future antiviral strategies against JEV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.